title: [The specific features of delivery in women with gestosis and myopia].
abstract: The treatment option for retinal degeneration, including peripheral vitreochorioretinal degenerations, was performed in 415 pregnant females (including 25 healthy pregnant females); it differed in patients with myopia and gestosis at labor and in the postpartum period in the fact that regularity was first revealed at labor: increases in cardiac output and cerebral circulation index and a decrease in uveal tract blood filling (rheographic quotient, Rq) from 1.78 to 0.5-0.7 per thousand. This results in retinal tissue hypoxia and dystrophy to give rise to free radical oxidation products. The treatment is that vasodilators increasing uveal tract blood filling by 0.9 per thousand are intravenously injected. Prolonged epidural anesthesia used during administrations of spasmolytics and vasodilators additionally shows a 0.9 per thousand increase in Rq in parturients with myopia and gestosis. Antioxidants that inhibit free radical oxidation products are used in the lipoprotein complexes of retinal cells and retinal degeneration are prevented and treated.
authors.forename: A G
authors.initials: AG
authors.lastname: Travkin
authors.forename: L S
authors.initials: LS
authors.lastname: Logutova
authors.forename: K N
authors.initials: KN
authors.lastname: Akhvlediani
authors.forename: T Kh
authors.initials: TKh
authors.lastname: Petrova
authors.forename: M V
authors.initials: MV
authors.lastname: Bogorad
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use; D001783:Blood Flow Velocity / Q000502:physiology; D036861:Delivery, Obstetric; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009216:Myopia / Q000150:complications* / Q000503:physiopathology; D049590:Postpartum Period; D011225:Pre-Eclampsia; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D012164:Retinal Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D014602:Uvea / Q000098:blood supply; D014665:Vasodilator Agents / Q000627:therapeutic use